Showing results (121-130 of 178) with videos related to
Sort By:
Pageof 18
Annals of the Rheumatic Diseases|February 25, 2022
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio StudyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.Current Rheumatology Reports|September 28, 2023
Oral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current LiteratureEva Vermeer, Renske C F Hebing, Maartje M van de Meeberg, et al.Arthritis and Rheumatism|October 31, 2009
Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitisMirjam K de Vries, Izhar C van Eijk, Irene E van der Horst-Bruinsma, et al.RMD Open|March 9, 2021
Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trialLaurette van Boheemen, Samina Turk, Marian van Beers-Tas, et al.Trials|June 20, 2021
Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trialMaike H M Wientjes, Sadaf Atiqi, Gerrit Jan Wolbink, et al.BMC Musculoskeletal Disorders|August 1, 2015
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 3, 2023
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic MonitorJette A van Lint, Naomi T Jessurun, Sander W Tas, et al.Arthritis Research & Therapy|May 23, 2016
Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional studySophie J Bernelot Moens, Fleur M van der Valk, Aart C Strang, et al.Arthritis Research & Therapy|June 23, 2023
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world studyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.Clinical and Experimental Rheumatology|January 21, 2015
C-reactive protein polymorphisms influence serum CRP-levels independent of disease activity in ankylosing spondylitisTheodora A M Claushuis, Mirjam K de Vries, Mignon A C van der Weijden, et al.Pageof 18